Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Marco Groß-Langenhoff"'
Autor:
Alexander E. Perl, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Nicki Panoskaltsis, Christian Recher, Catherine C. Smith, Mark J. Levis, Stephen Strickland, Christoph Röllig, Marco Groß-Langenhoff, Wen-Chien Chou, Je-Hwan Lee, Hisayuki Yokoyama, Nahla Hasabou, Qiaoyang Lu, Ramon V. Tiu, Jessica K. Altman
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 5, Pp 1-9 (2022)
Abstract The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemoth
Externí odkaz:
https://doaj.org/article/177517e470014866a24e2133dc705fd7
Publikováno v:
Urologia Internationalis. 100:66-71
Introduction: We evaluated the efficacy and tolerability of 3- and 6-month leuprorelin acetate (LA) depot formulations (Eligard®, Astellas Pharma GmbH) in patients with advanced prostate cancer treated in routine clinical practice in Germany. Materi
Autor:
Alexander E Perl, Jessica K Altman, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Catherine C Smith, Mark J Levis, Christoph Röllig, Marco Groß-Langenhoff, Nahla Hasabou, Qiaoyang Lu, Ramon V Tiu
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S210
Autor:
Alexander E Perl, Jessica K Altman, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Catherine C Smith, Mark J Levis, Christoph Röllig, Marco Groß-Langenhoff, Nahla Hasabou, Qiaoyang Lu, Ramon V Tiu
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S280
Autor:
Christoph Röllig, Ramon V. Tiu, Nahla Hasabou, Qiaoyang Lu, Giovanni Martinelli, Pau Montesinos, Nikolai A. Podoltsev, Marco Groß-Langenhoff, Mark J. Levis, Jessica K. Altman, Alexander E. Perl, Catherine C. Smith, Naoko Hosono
Publikováno v:
Blood. 136:22-23
Background: Gilteritinib is a FLT3 inhibitor with demonstrated efficacy and safety in patients with FLT3-mutated relapsed or refractory (R/R) AML. The efficacy of gilteritinib in patients with prior tyrosine kinase inhibitor (TKI) therapy is not clea
Autor:
Anita Schultz, Joachim E. Schultz, Arnulf Stenzl, Florian Altenberend, Marco Gross-Langenhoff
Publikováno v:
FEBS Journal. 275:1643-1650
The tandem GAF domain of human phosphodiesterase 11A4 (hPDE11A4) requires 72 μm cGMP for half-maximal effective concentration (EC50) of a cyanobacterial adenylyl cyclase used as a reporter enzyme. Here we examine whether modifications in the N-termi
Publikováno v:
Journal of Biological Chemistry. 281:2841-2846
N-terminal tandem GAF domains are present in 5 out of 11 mammalian phosphodiesterase (PDE) families. The ligand for the GAF domains of PDEs 2, 5, and 6 is cGMP, whereas those for PDEs 10 and 11 remained enigmatic for years. Here we used the cyanobact
Publikováno v:
BMC Pharmacology. 7
In mammals, cGMP is generated by soluble and membrane-bound guanylyl cyclases and can be degraded by altogether eight out of 11 mammalian PDE families. Apart from cGMP-activated protein kinases and from cGMPgated cation channels 5 of the 11 PDE famil
Publikováno v:
Journal of Clinical Oncology. 33:e16098-e16098
e16098 Background: Androgen-deprivation therapy is the current standard therapy for advanced prostate cancer (PCa), primarily consisting of injections of luteinizing hormone-releasing hormone agoni...